Capital Investment Advisory Services LLC Grows Position in Bristol-Myers Squibb (NYSE:BMY)

Capital Investment Advisory Services LLC lifted its position in Bristol-Myers Squibb (NYSE:BMY) by 15.0% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 12,023 shares of the biopharmaceutical company’s stock after purchasing an additional 1,568 shares during the period. Capital Investment Advisory Services LLC’s holdings in Bristol-Myers Squibb were worth $617,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. RFG Advisory LLC raised its position in Bristol-Myers Squibb by 13.7% during the 3rd quarter. RFG Advisory LLC now owns 16,952 shares of the biopharmaceutical company’s stock valued at $984,000 after purchasing an additional 2,046 shares during the last quarter. Onyx Bridge Wealth Group LLC raised its holdings in Bristol-Myers Squibb by 25.3% in the 3rd quarter. Onyx Bridge Wealth Group LLC now owns 7,226 shares of the biopharmaceutical company’s stock worth $419,000 after purchasing an additional 1,457 shares in the last quarter. Fifth Third Wealth Advisors LLC lifted its position in shares of Bristol-Myers Squibb by 58.3% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 4,967 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 1,830 shares during the period. BTC Capital Management Inc. boosted its stake in shares of Bristol-Myers Squibb by 7.9% during the 3rd quarter. BTC Capital Management Inc. now owns 92,514 shares of the biopharmaceutical company’s stock valued at $5,370,000 after purchasing an additional 6,746 shares in the last quarter. Finally, Advisors Management Group Inc. ADV increased its position in shares of Bristol-Myers Squibb by 19.9% during the third quarter. Advisors Management Group Inc. ADV now owns 7,717 shares of the biopharmaceutical company’s stock valued at $448,000 after buying an additional 1,281 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Wells Fargo & Company upped their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Redburn Atlantic cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. Finally, Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Stock Performance

BMY stock opened at $49.14 on Tuesday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31. Bristol-Myers Squibb has a 1 year low of $47.58 and a 1 year high of $70.93. The company has a market cap of $99.59 billion, a P/E ratio of 12.73, a price-to-earnings-growth ratio of 1.48 and a beta of 0.39. The stock’s fifty day moving average price is $51.22 and its 200-day moving average price is $51.38.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. The business had revenue of $11.48 billion during the quarter, compared to the consensus estimate of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.82 EPS. On average, equities analysts forecast that Bristol-Myers Squibb will post 6.63 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be paid a $0.60 dividend. The ex-dividend date is Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.88%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 62.18%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.